130 related articles for article (PubMed ID: 10913587)
1. Evaluation of anti-scratch properties of oxatomide and epinastine in mice.
Inagaki N; Nagao M; Nakamura N; Kawasaki H; Igeta K; Musoh K; Nagai H
Eur J Pharmacol; 2000 Jul; 400(1):73-9. PubMed ID: 10913587
[TBL] [Abstract][Full Text] [Related]
2. Participation of histamine H1 and H2 receptors in passive cutaneous anaphylaxis-induced scratching behavior in ICR mice.
Inagaki N; Nakamura N; Nagao M; Musoh K; Kawasaki H; Nagai H
Eur J Pharmacol; 1999 Feb; 367(2-3):361-71. PubMed ID: 10079012
[TBL] [Abstract][Full Text] [Related]
3. Effects of histamine H1 receptor antagonists on compound 48/80-induced scratching behavior in mice.
Sugimoto Y; Umakoshi K; Nojiri N; Kamei C
Eur J Pharmacol; 1998 Jun; 351(1):1-5. PubMed ID: 9698198
[TBL] [Abstract][Full Text] [Related]
4. Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes.
Mita H; Shida T
Arzneimittelforschung; 1995 Jan; 45(1):36-40. PubMed ID: 7893266
[TBL] [Abstract][Full Text] [Related]
5. VUF-K-8788, a periphery-selective histamine H1 antagonist with anti-pruritic activities.
Takizawa T; Matsumoto J; Tohma T; Kanke T; Wada Y; Nagao M; Inagaki N; Nagai H; Zhang MQ; Timmerman H
Jpn J Pharmacol; 2001 May; 86(1):55-64. PubMed ID: 11430473
[TBL] [Abstract][Full Text] [Related]
6. Scratching behavior in various strains of mice.
Inagaki N; Nagao M; Igeta K; Kawasaki H; Kim JF; Nagai H
Skin Pharmacol Appl Skin Physiol; 2001; 14(2):87-96. PubMed ID: 11316967
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of oxatomide on oxygen-radical generation and peptide-leukotriene release from guinea pig eosinophils.
Ohmori K; Manabe H; Akuta-Ohnuma K
Arzneimittelforschung; 1998 Jan; 48(1):43-6. PubMed ID: 9522030
[TBL] [Abstract][Full Text] [Related]
8. Participation of proteinase-activated receptor-2 in passive cutaneous anaphylaxis-induced scratching behavior and the inhibitory effect of tacrolimus.
Zhu Y; Peng C; Xu JG; Liu YX; Zhu QG; Liu JY; Li FQ; Wu JH; Hu JH
Biol Pharm Bull; 2009 Jul; 32(7):1173-6. PubMed ID: 19571380
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects.
Matsushita N; Aritake K; Takada A; Hizue M; Hayashi K; Mitsui K; Hayashi M; Hirotsu I; Kimura Y; Tani T; Nakajima H
Jpn J Pharmacol; 1998 Sep; 78(1):11-22. PubMed ID: 9804057
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist ramatroban on allergic rhinitis model in mice.
Suzuki Y; Inoue T; Yamamoto A; Sugimoto Y
Biol Pharm Bull; 2011; 34(4):507-10. PubMed ID: 21467637
[TBL] [Abstract][Full Text] [Related]
11. Effect of the new antiallergic drug epinastine on chemical mediator induced bronchoconstrictions in guinea pigs.
Misawa M; Kanai Y
Arzneimittelforschung; 1991 Nov; 41(11):1145-9. PubMed ID: 1725697
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of passive cutaneous anaphylaxis-associated scratching behavior by mu-opioid receptor antagonists in ICR mice.
Inagaki N; Nakamura N; Nagao M; Kawasaki H; Nagai H
Int Arch Allergy Immunol; 2000 Dec; 123(4):365-8. PubMed ID: 11146395
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological studies on the novel antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various experimental models.
Matsushita N; Hizue M; Aritake K; Hayashi K; Takada A; Mitsui K; Hayashi M; Hirotsu I; Kimura Y; Tani T; Nakajima H
Jpn J Pharmacol; 1998 Sep; 78(1):1-10. PubMed ID: 9804056
[TBL] [Abstract][Full Text] [Related]
14. Topical application of luteolin inhibits scratching behavior associated with allergic cutaneous reaction in mice.
Baolin L; Weiwei W; Ning T
Planta Med; 2005 May; 71(5):424-8. PubMed ID: 15931580
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effects of anti-pruritic drugs on scratch responses using histamine H1 receptor-deficient mice.
Sugimoto Y; Nakamura Y; Hossen MA; Watanabe T; Kamei C
Eur J Pharmacol; 2003 May; 470(1-2):113-6. PubMed ID: 12787839
[TBL] [Abstract][Full Text] [Related]
16. Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis.
Ogura N; Fujisawa K; Kato M
J Ocul Pharmacol Ther; 2024 Apr; 40(3):173-180. PubMed ID: 38150534
[No Abstract] [Full Text] [Related]
17. Anti-allergic and anti-inflammatory properties of a potent histamine H1 receptor antagonist, desloratadine citrate disodium injection, and its anti-inflammatory mechanism on EA.hy926 endothelial cells.
Jie Q; Kodithuwakku ND; Yuan X; He G; Chen M; Xu S; Wu Y
Eur J Pharmacol; 2015 May; 754():1-10. PubMed ID: 25704613
[TBL] [Abstract][Full Text] [Related]
18. Effect of epinastine hydrochloride on murine self-scratching behavior after skin-scratching stimulation.
Yilinuer H; Yamaoka J; Kawana S
Arch Dermatol Res; 2010 Jan; 302(1):19-26. PubMed ID: 19937255
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the antihistamine effect of TAK-427, a novel imidazopyridazine derivative.
Fukuda S; Midoro K; Yamasaki M; Gyoten M; Kawano Y; Fukui H; Ashida Y; Nagaya H
Inflamm Res; 2003 May; 52(5):206-14. PubMed ID: 12813625
[TBL] [Abstract][Full Text] [Related]
20. A comparison of Cetirizine, Ebastine, Epinastine, Fexofenadine, Terfenadine, and Loratadine versus placebo in suppressing the cutaneous response to histamine.
Grant JA; Danielson L; Rihoux J; DeVos C
Int Arch Allergy Immunol; 1999; 118(2-4):339-40. PubMed ID: 10224437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
